1. AD pathology and β-amyloid plaques {#S1}
=====================================

Alzheimer's disease (AD) is characterized by the presence of extracellular senile beta-amyloid (Aβ) plaques and intracellular neurofibrillary tau tangles, however, other disease pathology features include the loss of cholinergic neurons and synapses, the loss of white matter, congophilic/cerebral amyloid angiopathy (CAA), inflammation, oxidative stress and cerebrovascular dysfunction ([@R65]; [@R68]; [@R70]; [@R77]). Senile plaques are primarily composed of Aβ peptides, byproducts of amyloid precursor protein (APP) metabolism following its sequential cleavage by the enzymes β- and γ-secretase, which results in the generation of two Aβ species: Aβ~40~ and Aβ~42~ ([@R47]). Aβ~40~ is the more prevalent isoform found in vivo and serves as a major component of CAA ([@R47]; [@R77]). Aβ~42~ makes up only 10% of the total Aβ, but is the more predominant toxic species found in plaques due to its enhanced hydrophobicity, aggregation and fibrillization potential. It can spontaneously self-aggregate to generate soluble neurotoxic oligomers or insoluble fibrils that form plaques ([@R47]; [@R70]). Neuritic or dense-core senile plaques contain Aβ fibrils arranged radially into a central core. More importantly, these plaques are typically surrounded by dystrophic neurites, reactive astrocytes, activated microglial cells, and synaptic loss, indicating that these cells may play an important role in disease pathology ([Fig. 1A](#F1){ref-type="fig"}). Abnormal mitochondria and lysosomes have also been found within these activated cells, indicating that energy or protein degradation processes may be compromised. In addition, there is also evidence that Aβ plaques are directly associated with brain vessels, indicating that blood vessel proximity may play a role in plaque formation and/or remodeling ([@R46]).

2. Inflammatory processes around β-amyloid plaques in AD {#S2}
========================================================

In AD brains, Aβ plaques are surrounded by activated microglial cells and reactive astrocytes. In addition, several inflammation-related mediators have been found within plaques. Microglia are considered the resident macrophages of the CNS and serve as important players in driving the inflammatory response in AD ([@R91]). However, they also prove vital in promoting and maintaining a healthy CNS ([@R76]). Using their highly motile processes they constantly sample and survey their surrounding microenvironment making them the first line of defense against pathogens and injury in the brain ([@R29]; [@R91]). Without physiological stress, microglia display a ramified or deactivated phenotype secreting anti-inflammatory and neurotrophic factors ([@R29]; [@R43]). Histological studies have shown that activated (amoeboid) microglia surround senile plaques in AD brains, along with astrocytes, and that these cells stain positive for inflammatory markers including major histocompatibility complex (MHC) class II, cyclooxygenase (COX)-2, monocyte chemoattractant/chemotactic protein (MCP)-1, tumor necrosis factor (TNF)-α, interleukin (IL)-1β, or IL-16 ([@R2]; [@R29]). However, the role of these cells is somewhat complex. On one side, data indicates that microglia are poor phagocytes of Aβ and thus cannot play a significant role in Aβ clearance or plaque remodeling, either promoting or protecting against Aβ-induced pathology ([@R27]; [@R31]). On the other side, reports indicate that microglial cells are capable of remodeling and enhancing the clearance of Aβ plaques ([@R11]; [@R27]; [@R44]). Despite these findings, it is becoming more accepted that microglia activation (and the release of neurotoxic factors) is a secondary event following Aβ deposition and aggregation ([@R76]).

3. The migration of blood cells into the CNS {#S3}
============================================

The brain employs several immune control mechanisms to tightly regulate inflammation and its potential brain damage-promoting pathways ([@R72]). One important feature of this immune privilege involves the blood--brain barrier (BBB), which in the context of inflammation, is responsible for restricting the entry of substrates and cells into the brain ([@R72]). During an effective immune response, vascular permeability is increased along with blood flow to the site of inflammation or injury. This is accompanied by the selective entry of immune cells from the periphery, which help further propagate an inflammatory response by producing cytokines and carrying out other important effector cell functions ([@R95]). Migration from the blood into the brain occurs at post capillary venules and involves a multiple-step process of events that are mediated by various chemokines, their associated receptors and adhesion molecules.

Peripheral immune cell migration into the CNS resembles typical leukocyte extravasation into other organs. There are four 'classic' steps of immune cell extravasation including: 1) capture (tethering) and rolling, which involves the interaction of selectins and mucins and/or integrins and IgG members; 2) activation, which is propagated by chemokines leading to integrin activation; 3) arrest, which is mediated through integrins and their counter-ligands; and 4) diapedesis or transmigration ([@R74]). First, immune cells roll along the endothelium. This is initiated by selectin binding resulting in the 'tethering' of the immune cell to the endothelium (this involves e.g., P-selectin and very late antigen-4 (VLA-4)) ([@R56]). Interestingly, a subset of immune cells also patrols the resting endothelium circulating against the direction of blood flow; dependent on the interaction of a specific integrin, e.g., the chemokine receptor CX~3~CR1 ([@R69]). During the process of rolling and tethering, engagement with a chemoattractant can lead to integrin activation on the immune cells and increased affinity of the integrin for its associated adhesion molecule on the endothelium. This ultimately leads to immune cell adhesion. Following adhesion, the immune cell undergoes transendothelial migration or extravasation from the blood vessel. These early transmigration events involve e.g., platelet endothelial cell adhesion molecule (PECAM-1), a cell adhesion molecule expressed on endothelial cells, and e.g., RAGE, which is a receptor for macrophage 1 (MAC-1; CD11b) ([@R56]). Once across the endothelium and basement membrane, the immune cell crosses the perivascular space and glia limitans and migrates towards the source of the chemoattractant (i.e., the site of inflammation). In vitro studies have demonstrated that Aβ promotes the expression of adhesion molecules and can enhance immune cell adhesion and subsequent transmigration across the BBB.

3.1. Red blood cells in the AD brain {#S4}
------------------------------------

Although alterations have been found in red blood cells isolated from AD patients ([@R6]; [@R15]; [@R61]; [@R75]; [@R98]), there is no indication that these cells infiltrate the AD brain nor that such infiltration plays a role in disease progression. It could, however, be possible that these cells affect leukocyte infiltration into the CNS. In AD, red blood cells show membrane alterations as well as impairments in their oxygen delivery capabilities ([@R61]), which could result in aggravating oxidative stress and vascular injury, ultimately leading to enhanced endothelial permeability and the infiltration of peripheral immune cells.

3.2. Platelets in the AD brain {#S5}
------------------------------

Platelets are responsible for maintaining the integrity of blood vessels and promoting hemostasis. These cells are of particular interest in AD since they contain high amounts of APP and release Aβ~40~ into the blood stream ([@R20]). Furthermore, studies have shown that the larger 130 kDa APP isoform is significantly reduced in platelets isolated from AD patients, implicating their potential role in altered APP metabolism (or use in the development of AD biomarkers) ([@R67]). Vascular injury or stimulation via Aβ could result in platelet activation and adhesion to the vessel wall. These studies along with others provide increasing evidence that platelet activation contributes to CAA. In this context, activated platelets in turn could produce more Aβ as well as chemokines ([@R98]), promoting immune cell infiltration. In fact, platelets are known amplifiers of leukocyte adhesion ([@R89]). A recent study by Thornton and colleagues demonstrated that platelets secrete IL-1α, which drives the transendothelial migration of neutrophils in vitro ([@R85]). However, thus far there have been no indications that platelets migrate into the AD brain ([@R45]).

3.3. Leukocytes in the AD brain {#S6}
-------------------------------

Leukocytes are considered the immune cells of the periphery and can be divided into granulocytes including basophils (\<1%), eosinophils (\<6%), and neutrophils (40--75%), and lymphocytes (20--45%) including T cells, B cells, and natural killer cells and monocytes (2--10%). Although the AD brain does not present prominent infiltration of peripheral leukocytes such as those seen in other neuroinflammatory diseases (e.g., multiple sclerosis), recent studies indicate that their infiltration does occur and is stimulated by Aβ ([@R72]). For instance, early investigations demonstrated that Aβ infusion in rats results in the adhesion and migration of leukocytes across arteries, venules and cerebral vessels ([@R74]). However, whether this infiltration does indeed occur in AD and by which particular cell type, remain under intense debate.

### 3.3.1. Granulocytes {#S7}

Neutrophils are the most abundant population of cells in the peripheral blood accounting for 40--75% of leukocytes in human blood. These cells specialize in phagocytosis, rapidly mobilizing to areas of infection and known for their ability to work in anaerobic conditions. However, the lifespan and functional role of neutrophils during an innate immune response is relatively short-lived, compared to macrophages, which help propagate and sustain a local response. Neutrophil infiltration into the CNS has been implicated in CNS diseases involving an inflammatory reaction (e.g., bacterial meningitis) ([@R71]), however, whether this migration takes place under chronic neuroinflammatory conditions (e.g., multiple sclerosis and AD) remains unknown. In AD, one recent study reports that Ly6C/G (Gr-1)+ (a marker for cells of the myeloid lineage) cells migrate towards Aβ plaques in an AD disease mouse model. Using 2-photon microscopy the authors observed dynamic extravasation of these cells from blood vessels into the brain parenchyma of 9- to 13-month-old 5XFAD mice ([@R4]). Although the underlying mechanism for this migration is still unclear, data from these experiments indicates that Aβ plaques, but not soluble Aβ, may play an important role in recruiting these cells from the blood. A previous study in neutrophils has shown that serpin-enzyme complex (SEC) receptor mediates the chemotaxis of these cells in response to the Aβ~25--35~ peptide ([@R41]). Thus, it could be possible that depending on the species of Aβ, different inflammatory responses (i.e., an early and short proinflammatory burst response vs. a low and chronic response) may be generated based on the activation of specific receptors and pathways. However, a more detailed discussion of this issue can be found in the monocyte section.

### 3.3.2. Lymphocytes {#S8}

Although peripheral lymphocyte migration is a not prominent feature in the AD brain like other neurodegenerative diseases (i.e., multiple sclerosis), T cell infiltration has been observed in the brains of AD patients ([@R40]; [@R73]; [@R86]; [@R87]), albeit at low numbers ([@R53]; [@R74]). In addition to the brain parenchyma, alterations in T cells have been detected in the periphery of AD patients ([@R49]; [@R62], [@R63]) and CD4+ and CD8+ T cells have been found associated with CAA pathology, in addition to monocytes and macrophages in leptomeningeal and cortical vessels ([@R92]). Previous investigations have shown that peripheral T cells in AD patients overexpress chemokines and receptors (i.e., MIP-1α and CXCR2) associated with T cell migration across the endothelium ([@R52]; [@R57]). Furthermore, hippocampal Aβ injection in the rat results in the upregulation of receptors (i.e., RAGE, CCR5) involved in promoting T cell migration into the brain ([@R51]).

Despite these findings, it still remains unclear how T cells enter the brain through the BBB and what specific stimulus is responsible for T cell accumulation in the AD brain ([@R63], [@R64]; [@R74]). Recent in vitro studies suggest that Aβ~1--42~-treated microglia release TNF-α to promote transendothelial migration of T cells via MHC I expression ([@R94]). In addition, studies involving Aβ immunization have indicated that CD11c+ dendritic cells may stimulate Aβ-specific T cells to target Aβ depositions in the brain ([@R25]). Specific cytokines may also play an important role in T cell infiltration. A previous study by Buckwalter and colleagues showed that local expression of TGF-β1 increases both meningeal and parenchymal T cell number in a mouse model of AD following Aβ~1--42~ immunization ([@R10]).

It also remains unclear what role these cells play in disease pathology and cognitive outcome. Previous studies indicate that T cells in the CNS can both promote and impair cognitive processes based on their given subtype ([@R19]). Specifically, recent preliminary data indicates that transferring Aβ-specific Th1 cells enhances Aβ plaque development in APP-swe/PS1dE9 mice, whereas transferring Aβ-specific Th2 cells has no effect. Interestingly, the transfer of Th17 cells reduces Aβ concentrations in the hippocampus ([@R54]). In another study, systemic transplantation of T regulatory cells ameliorates cognitive impairment and reduces Aβ plaque deposition and soluble Aβ levels. This treatment also resulted in a reduction in microglial activation and systemic inflammatory factors ([@R94]). Although not characterized from the periphery, a recent study showed that intracerebroventricular-injected Th1 CD4+ T cells are able to migrate within the brain parenchyma associated with increased expression of ICAM-1 and MHC II. This study also shows that these T cells effectively target Aβ plaques, increase Aβ uptake and promote neurogenesis in a mouse model of AD ([@R25]). In addition, these authors have shown that T cell migration towards Aβ plaques and significant plaque clearance also occur in APP/IFN-γ double transgenic mice following Aβ immunization ([@R24]). However, in both transgenic mice and AD patients this Aβ immunization results in meningoencephalitis ([@R10]; [@R25]).

### 3.3.3. Monocytes {#S9}

Monocytes represent 2--10% of peripheral blood leukocytes in humans and rodents. They are generated from myeloid precursor cells in the bone marrow and released into the bloodstream where they circulate before entering organs and differentiating into tissue-specific macrophages and dendritic cells ([@R99]). Monocytes are characterized morphologically as mononuclear cells with bean-shaped nuclei and phenotypically by their expression of surface markers. There are a wide variety of phenotypically and functionally heterogeneous monocyte subpopulations varying in maturation, differentiation, and activation states based on their differential expression of these surface markers ([@R3]; [@R9]; [@R79]).

In humans, monocytes are identified by their expression of CD14 and CD11b and further characterized into heterogeneous subsets by their differential expression of CD14 and CD16. Mouse monocytes are defined by their expression of CD11b (membrane-activating complex 1 (Mac-1)), CD115 (M-CSF receptor), and F4/80 ([@R83]). In both humans and rodents, there are two main subpopulations that divide monocytes phenotypically and functionally: 'classical' or 'inflammatory' monocytes (Ly6C+ in mice), which express higher levels of CCR2, and 'non-classical' or 'resident' monocytes (Ly6C- in mice), which express higher levels of CX~3~ chemokine receptor 1 (CX~3~CR1; fractalkine) ([@R96]). [@R58] recently showed in mice that patrolling (Ly6C^lo^) monocytes are attracted to the walls of Aβ-positive veins. Although more functional studies are needed to help distinguish their distinct functional and physiological roles, recent studies in rodent models have concluded that CCR2-expressing monocytes are recruited to sites of inflamed or injured tissue, whereas CX~3~CR1-expressing cells exhibit more patrolling behavior and involvement in tissue maintenance ([@R30]; [@R83]).

Monocytes play an important role during innate and adaptive immune responses ([@R84]; [@R99]). Inflammation and other injury lead to an increased recruitment of monocytes to peripheral tissues aiding in host immune system defense and repair. During an inflammatory response, monocytes are recruited to the sites of inflammation by CCL2 (classical monocytes) or CX~3~ chemokine ligand 1 (CX3CL1; resident monocytes) and subsequently differentiate into effector cells ([@R99]). Depending on their surface marker expression, monocytes can further propagate the immune response by secreting inflammatory mediators including cytokines and chemokines (proinflammatory monocytes), by giving rise to antigen-presenting cells including macrophages and dendritic cells, or by performing antigen-presenting cell activity themselves (i.e., tissue repair and phagocytosis) ([@R43]).

3.4. Monocyte-derived neurotoxicity {#S10}
-----------------------------------

The role of monocytes and monocyte-derived cells in the propagation of neurodegenerative disease is still under intense debate. Similar to microglia, these cells may induce beneficial effects, but also contribute to neurodegeneration through uncontrolled inflammation and/or neurotoxic pathways. Previous studies have shown that microglia and THP-1 monocytes can interact with fibrillar Aβ and stimulate the production of proinflammatory cytokines, reactive oxygen species (ROS), and neurotoxic secretory molecules, ultimately resulting in neuronal apoptosis ([@R13]). Specifically, studies have demonstrated that CD36, a class B scavenger receptor, CD47, an integrin-associated protein, and α~6~β~1~-integrin form a cell surface receptor complex that mediates the binding of microglia or THP-1 monocytes to Aβ fibrils. This binding subsequently activates a tyrosine kinase intracellular signaling cascade stimulating IL-1β, TNF-α and ROS production ([@R5]). In line with these studies, El Khoury and colleagues have also shown that CD36 can mediate the response of microglia and macrophages to Aβ, including promoting the secretion of H~2~O~2~, cytokines, chemokines and ROS ([@R14]; [@R17]). In addition to CD36, recent investigations have also identified the NOD-like receptor family, pyrin domain containing 3 (NLRP3) inflammasome as an important mediator of microglia/monocyte-induced neurotoxicity. These studies have demonstrated that fibrillar Aβ can act as an activator of inflammasomes, which promotes caspase-1 signaling and the subsequent release of IL-1β, IL-18, IL-1α proinflammatory cytokines ([@R78]). Converging evidence indicates that phagocytosis of Aβ (through the interaction of CD36 and a TLR heterodimer of TLR4-TLR6) and subsequent loss of lysosome integrity, triggered by aggregated or insoluble material, result in the release of lysosomal content (e.g., cathepsin B and/or ROS) and assembly of the inflammasome ([@R32]; [@R78]). Thus, it appears that the engulfment and endocytosis of Aβ by macrophages results in the conversion of soluble Aβ into its more fibrillar or pathogenic form, ultimately triggering dysfunctional degradation/lysosome damage and activating the inflammasome and release of proinflammatory and neurotoxic molecules ([@R78]). Interestingly, a recent study by Heneka and colleagues has shown that a deficiency in the NLRP3 inflammasome results in the skewing of microglial cells towards a more M2 or anti-inflammatory phenotype, as well as, attenuates amyloid accumulation in an AD mouse model ([@R34]). Together, these studies indicate that microglia and monocyte-derived cells also play an important role in promoting proinflammatory and neurotoxic pathways. Thus, developing strategies against chronic monocyte/microglial cell inflammatory activation may prove beneficial for AD neurodegeneration. In support of this, recent investigations have shown that the use of peroxisome proliferator-activated receptor γ (PPARγ) agonists, which suppress inflammatory gene expression, ameliorate spatial memory performance in an AD mouse model. The authors report that treatment of a PPARγ agonist results in the enhanced phagocytosis of Aβ by microglial cells (mediated by increased CD36 expression) as well as the reduction of cortical and hippocampal Aβ levels ([@R93]).

3.5. Implications for monocyte-derived recruitment, phagocytosis and therapeutic use in AD {#S11}
------------------------------------------------------------------------------------------

Emerging evidence from studies in stroke, brain trauma, and AD indicate that these severe brain disorders can lead to BBB breakdown and subsequent migration of blood-derived monocytes into the CNS ([@R56]). Interestingly, post-mortem brain sections of AD patients with co-morbid stroke exhibit deposition of brain-infiltrating macrophages containing Aβ fibrils (Wiesniewski et al., 1991; [@R1]). Despite the detrimental role of leukocyte infiltration in some neurological disorders, accumulating data indicates that peripheral monocytes may be beneficial to AD in ameliorating disease pathology and progression.

One of the first studies to demonstrate the benefits of monocytic cells was the investigation performed by Simard and colleagues in mice, which showed that blood-derived microglia (now referred to as bone marrow-derived/blood-derived monocytes or macrophages) are recruited to sites of Aβ plaque deposition (triggered by Aβ~40~ and Aβ~42~) and can eliminate Aβ deposits via phagocytosis ([@R80]). Following this study, El Khoury et al. demonstrated that CCR2 deficiency, or disrupting the recruitment and accumulation of mononuclear phagocytes (i.e., microglia/blood-derived monocytes) to lesion sites, impairs the accumulation of these cells near Aβ plaques and accelerates Aβ plaque burden in AD transgenic mice ([@R18]). Together, these studies indicate that blood-derived monocytes play an important neuroprotective role via Aβ clearance. In support of these findings, others have shown that stimulating the infiltration or turnover of peripheral monocytic cells (e.g., blocking immunosuppressive TGF-β or administrating M-CSF, granulocyte colony-stimulating factor (G-CSF), granulocyte macrophage colony-stimulating factor (GM-CSF), chitin, or LPS, or NGF) can attenuate AD pathology (i.e., reducing parenchymal and cerebrovascular Aβ deposition) and cognitive deficit in AD rodent models ([@R7]; [@R33]; [@R56]; [@R66]; [@R72]; [@R88]; [@R95]; [@R37]). In addition to eliminating Aβ deposits and preventing plaque formation, these cells (mainly the anti-inflammatory subset) are also capable of arresting the local production of proinflammatory factors (e.g., TNF), enhancing neurogenesis, releasing proteolytic enzymes and proteinases, and producing reparative growth factors (e.g., insulin-like growth factor I, IGF-I) ([@R27]; [@R56]; [@R76]).

However, there is still some controversy regarding monocyte infiltration in the AD brain. Our lab and other researchers have provided convincing in vitro data indicating that the transmigration of monocytes into the CNS is a specific response to Aβ ([@R21]; [@R28]; [@R38]; [@R56]). In support of these findings, others have shown that this is also true in vivo. Lebson et al. recently reported that significant monocyte deposition is present only in the brains of AD transgenic mice, neighboring Aβ plaques, whereas little or no cell deposition is present in the brains of control animals ([@R50]; [@R55]; [@R82]). Unlike other studies, which show monocyte infiltration following irradiation and bone-marrow transplant, this study indicates that monocytes can infiltrate the AD mouse brain without prior irradiation-related BBB damage. Furthermore, Lampron and colleagues demonstrated that the formation of Aβ plaques in an AD mouse model is sufficient to induce bone marrow-derived cell entry into the CNS without irradiation, albeit at low numbers ([@R48]).

In addition to chemokine receptors like CCR2, formylpeptide receptors (FPRs) are also recognized as another group of classical chemoattractant receptors involved in leukocyte trafficking ([@R12]). A previous investigation in human peripheral blood monocytes, demonstrated that chemotaxis towards Aβ and APP occurs via the activation of formyl peptide receptor like-1 (FPRL1), a low affinity receptor located on leukocytes and mononuclear phagocytes ([@R42]). Interaction of FPRL1 or its mouse homolog FPR2 with Aβ results in the internalization of Aβ by macrophages, enhanced chemotactic activity, as well as the release of neurotoxic substances ([@R39]).

Extensive evidence indicates that CCL2 and CX~3~CL1 play an important role in monocyte trafficking during inflammatory disorders including AD ([@R35]). Some hypothesize that the CCL2/CCR2 pathway is involved in monocytic trafficking out of the bone marrow and into the blood, while the CX~3~CL1/CX~3~CR1 pathway is involved in the capture and adhesion of monocytes to the vessel wall near the barrier of the inflamed tissue ([@R35]). Thus, it could be possible that FPRs may play a distinct role in local monocyte or mononuclear phagocyte recruitment, in which cells from the perivascular space or non-lesioned parenchyma (where Aβ deposition is not apparent) are recruited to areas of the parenchyma where senile plaques and Aβ accumulation are prevalent.

Extensive in vivo and in vitro evidence indicates that blood-derived monocytes can phagocytose Aβ ([@R33]; [@R56]; [@R88]), however, the exact mechanism of how monocytes clear Aβ remains unclear. As previously mentioned, several studies have demonstrated that insoluble fibrillar Aβ, the aggregated form of Aβ found in senile plaques, can bind to receptors on microglia and activate these cells to produce cytokines, chemokines, and reactive oxygen and nitrogen species. The receptors involved in promoting this binding and/or phagocytosing fibrillar Aβ include: class A1 scavenger receptors (*Scara1*), class B2 scavenger receptors (*Scara2*), CD36, and RAGE ([@R26]). Other microglial receptors involved in Aβ uptake include TLR4/CD14, FPRL1, and complement receptors ([@R81]). These cells also produce a number of Aβ-degrading enzymes, including insulysin, neptrilysin, and others ([@R26]). However, again whether these same receptors and/or pathways are also involved in monocyte Aβ clearance remains unclear. Furthermore, it is important to consider the varying forms of Aβ and how these species stimulate differential activation of mononuclear phagocytes and their subsequent degradation of Aβ. Previous studies indicate that soluble Aβ is taken up via pinocytosis, whereas fibrillar Aβ is taken up by phagocytosis in macrophages/microglia ([@R81]). A recent study by Frenkel and colleagues indicates that *Scara1*, a scavenger receptor found on myeloid cells, serves as the main receptor for soluble Aβ clearance, rather than CD36 ([@R26]). Recent genome-wide association studies in AD patients have also identified a new susceptibility loci and possible receptor for altered Aβ processing: TREM2, a receptor involved in regulating phagocytosis and inflammatory responses in myeloid cells ([@R36]). Further studies are needed to distinguish which receptors and pathways distinguish successful phagocytosis from ineffective phagocytosis and whether this is cell type dependent (i.e., improved in monocytes vs. microglia) or Aβ species dependent.

The question remains, however, if blood-derived monocytes are recruited to the AD brain (either as a specific response to Aβ or a leaky BBB caused by vascular injury) and are effective phagocytes of Aβ (based on animal studies), then why does AD continue to progress? Furthermore, could it be possible that AD patients suffer from faulty immune signaling functions in respect to the infiltration, patrolling and/or phagocytic (e.g., toll-like receptor, TLR) abilities of these monocytic cells? To our knowledge, there have been no reports on the immune defects seen in mouse AD macrophages, however, reports have shown that the expression of receptors involved in Aβ uptake and Aβ-degrading enzymes, does decrease with age in AD mouse models ([@R26]). Thus, it could be possible that microglia and/or monocyte-derived cells could become dysfunctional, lose their ability to degrade Aβ, produce proinflammatory cytokines and neurotoxins, which in turn promote further Aβ production and accumulation ([@R36]).

Clinical investigations have shown that peripheral monocytic cells from AD patients appear ineffective at phagocytosing Aβ (altered TLR, MHC II, or COX-2, CCR2) and may even contribute to CAA ([@R23]; [@R56]; [@R59]; [@R97]). These patient studies using monocytes isolated from healthy individuals show that these cells can phagocytose and degrade Aβ as well as gain access to Aβ-positive vessels and ingest Aβ. Monocytes from AD patients, on the other hand, are unable to phagocytose Aβ as well as display lower expression of surface proteins involved in Aβ phagocytosis and pronounced apoptotic signaling ([@R22], [@R23]; [@R97]). These studies suggest that monocytes/macrophages may be contributing to CAA by releasing Aβ into the vessel walls following apoptosis ([@R56]). Thus, finding a way to promote effective Aβ clearance in these cells, while avoiding the activation of proinflammatory and neurotoxic pathways, should prove an attractive target for AD therapies. In a recent study by Mizwicki and colleagues, the authors treated peripheral blood mononuclear cells from AD patients with 1α,25-dihydroxyvitamin D3 (1,25D3), the active metabolite of vitamin D, and resolvin D1 (RvD1), a derivative of omega-3 fatty acids, in an effort to balance the activation of inflammation, specifically avoiding neurotoxic pathways and promoting effective Aβ phagocytosis. Their findings indicate that both 1,25D3 and RvD1 can enhance Aβ phagocytosis, inhibit soluble Aβ-induced production of proinflammatory cytokines and inhibit fibrillar Aβ-induced apoptosis ([@R60]). These studies are promising, however, further investigation is needed in order to determine whether such treatments will translate into neuroprotection and/or cognitive improvement. It could also be possible that AD patients exhibit enhanced levels of CCL2, which some investigators believe could result in desensitization of cells and thus impairment in their ability to infiltrate, respond to inflammatory or neuronal insult, or phagocytose Aβ ([@R59]; [@R66]).

3.6. Concluding remarks {#S12}
-----------------------

Taken together, these findings indicate that developing strategies to stimulate the production of new and functioning peripheral monocytic cells may prove an insightful avenue for further therapeutic development ([Fig. 1B](#F1){ref-type="fig"}). One such approach could involve genetically altering these cells to express therapeutic genes (e.g., signals or neuroprotective factors that help promote neuronal survival or Aβ clearance) and using these cells to deliver therapeutic substances/capabilities to lesion sites by exploiting their ability to home to regions of brain damage and Aβ deposition. The selective migration of monocytes towards Aβ plaque deposition makes these cells optimal candidates for the delivery of therapeutic substances to the AD brain.
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